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aBSTRaCT
OBJECTıVE: It is known that diabetes may cause to hypercoagulability. The pathogenetic mechanism 
of  coagulation  activation  is  not  completely  clear  and  the  origin  is  multifactorial.  While  chronic 
hyperglycemia is considered to be the main underlying pathology, there are various comments on 
the association between glycemic control and haemostatic disorders. In this study, we have aimed 
to compare patients with diabetic nephropathy and patients with idiopathic nephrotic syndrome with 
respect to haemostatic differences.
maTERıal	and	mETHOdS: We compared 10 newly diagnosed idiopathic nephrotic syndrome 
patients with 10 normoalbuminuric, 10 microalbuminuric and 10 macroalbuminuric Type II diabetic 
patients in terms of haemostatic disorders. We included 12 healthy controls in the study. In all groups, 
protein C activity, free protein S, Antithrombin III, Factor VII, VIII, IX, XI, plasminogen, fibrinogen 
and platelet count were evaluated. 
RESulTS: Antithrombin III levels of patients with nephrotic syndrome were significantly lower than 
the control group and macroalbuminuric diabetics but fibrinogen levels were significantly higher than 
controls. Fibrinogen levels of microlalbuminuric diabetics were significantly higher than controls. 
Other haemostatic parameters were all in normal range in all patient groups. 
COnCluSıOnS: These findings suggest that the mechanism of hypercoagulation works in a different 
pathway than the hypercoagulation in nephrotic patients.
KEY	wORdS: Antithrombin III, Diabetes mellitus, Fibrinogen, Nephrotic syndrome
öz
amaÇ:  Diyabetes  Mellitus’da  hiperkoagülabiliteye  eğilim  olduğu  bilinmektedir,  pıhtılaşma 
aktivasyonunun patogenetik mekanizması tam olarak açık değildir ve multifaktöriyel orijinlidir. Kronik 
hipergliseminin altta yatan esas patoloji olduğu kabul edilmekle birlikte, glisemik kontrolün hemostatik 
bozukluklarla  ilgisi  konusunda  değişik  yorumlar  mevcuttur.  Çalışmamızda,  diyabetik  nefropatili 
hastaları idiyopatik nefrotik sendromlu hastalarla hemostatik değişiklikler açısından değerlendirmeyi 
amaçladık.
GEREÇ	ve	YönTEmlER:	Bu amaçla, 10 yeni tanı almış idiyopatik nefrotik sendromlu hastayı 
normo- mikro- makroalbüminürik evredeki 10’ar tip II diyabetik hasta ve 12 sağlıklı kontrol grubu ile 
hemostatik parametreler açısından kıyas ettik. Tüm gruplarda aktive protein C, protein S, antitrombin 
III, Faktör VII, VIII, IX, XI, Plazminojen, fibrinojen çalışıldı. 
BulGulaR:  Nefrotik  sendromlu  hastaların  kontrol  grubu  ve  makroalbüminürik  hastalardan 
antitrombin  III  düzeyi  anlamlı  düşük,  fibrinojen  düzeyleri  ise  kontrol  grubundan  anlamlı  yüksek 
bulundu. Mikroalbüminürik hastaların fibrinojen düzeyi kontrol grubundan anlamlı yüksek bulundu.
Tüm gruplarda diğer hemostatik parametreler normal referans aralığı içerisindeydi.
SOnuÇ: Bu bulgular diyabetik hastalardaki koagülasyona eğilimin nefrotik sendromlu hastalardaki 
hiperkoagülasyon mekanizmalarından farklı yönde geliştiğini düşündürmektedir.
anaHTaR	SözCÜKlER: Antitrombin III, Diyabetes mellitus, Fibrinojen, Nefrotik sendrom
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at  least  twice  of  30  were  defined  as  microalbuminuria,  and 
excretion above 300 mg/day was defined as macroalbuminuria. 
The  values  over  30  mg/day  were  accepted  as  the  diabetic 
nephropathy course.
Haemogram, biochemical assays, HbA1C, activated protein 
C, free protein S levels, antithrombin III (AT-III), fibrinogen, 
Factor  VII,  VIII,  IX,  XI  levels,  plasminogen,  24-hour  urine 
protein, creatinine, microalbuminuria were evaluated in patient 
and control groups.
The  blood  samples  required  for  haematological  and 
biochemical parameters were collected intravenously following 
12 hours of fasting.
Biochemical  parameters  were  investigated  with  the 
Boehringer  Mannheim  747  autoanalyzer  using  Boehringer 
Mannheim kits.
Proteinuria in 24-hour urine and HbA1C were investigated 
with the same method, again with Boehringer Mannheim 747 
autoanalyzer using Boehringer Mannheim kits.
Blood  samples  were  collected  in  Becton  Dickinson 
Vacutainer tubes pre-filled with anticoagulant for all the blood 
counts, and the counts were performed with the automatic full 
blood count device Cell-Dyn 3500 R.
Blood  samples  were  collected  in  tubes  containing  3.2% 
trisodium citrate for fibrinogen, FVII, FVIII, FIX and FXI assays 
and  measurements  were  performed  with  the  coagulometric 
method  via  ACL  TOP  analyzer  using  RecombiPlasTin  2G, 
SynthASiL, Fibrinogen-C XL, FVII, FVIII, FIX, FXI deficient 
plasma kits from HemosIL.
For protein C activity, free protein S and antithrombin III, 
the  blood  samples  were  intravenously  collected  into  tubes 
containing 3.2% trisodium citrate following 12 hours of fasting. 
Protein C activity and free protein S were measured using the 
chromogenic method with the ACL TOP analyzer and protein 
C  activator  and  free  protein  S  kits  from  HemosIL.  AT  III 
levels were measured using the Beckmann Array 360 System 
nephelometer and automatically with Beckmann kits.
Blood  samples  were  intravenously  collected  into  tubes 
containing  3.2%  trisodium  citrate  for  plasminogen  analysis. 
Plasma  samples  were  separated  from  blood  by  centrifuging 
at 3500 rpm for 15 minutes and were stored at -80 ˚C until 
the analysis. Plasminogen was measured using the kits from 
HemosIL with ACL TOP analyzer via the chromogenic method.
Statistical	analysis
All  data  analyses  were  performed  using  commercially 
available software (PASW Statistics 18, SPSS, Inc., Chicago, 
IL; and SigmaStat 3.5, Systat Software, Inc., San Jose, CA). 
Continuous variables were demonstrated using n (sample size) 
and  mean,  and  standard  deviation;  and  categorical  variables 
using n (sample size) and median, and 25th and 75th percentiles. 
ınTROduCTıOn
In the majority of diabetic patients, mortality occurs due 
to disrupted coagulation mechanisms. 75% of the thrombotic 
death risk of 80% occurs due to cardiovascular complications 
and the remaining 5% occurs due to cerebrovascular events and 
peripheral vascular complications (1). Important findings such 
as increased coagulation potential, continuous activation of the 
haemostatic system, chronic platelet activation and decreased 
fibrinolytic potential have been demonstrated in diabetic subjects 
(2-4). The pathogenetic mechanism of coagulation activation 
in  diabetes  is  not  completely  clear  and  is  of  multifactorial 
origin. While chronic hyperglycemia is considered to be the 
main underlying pathology, there are various comments on the 
association between glycemic control and haemostatic disorders 
(5).
Patients with nephrotic syndrome (NS) are also predisposed 
to hypercoagulability. Studies show that these patients lose the 
natural anticoagulants such as protein C-S, antithrombin III and 
plasminogen via urine due to massive proteinuria. This suggests 
that coagulopathy develops due to the increased production of 
procoagulants in liver because of the loss of anticoagulants via 
urine or hypoalbuminemia (6, 7).
In  this  study,  we  have  aimed  to  compare  patients  with 
diabetic  nephropathy  and  patients  with  idiopathic  nephrotic 
syndrome with respect to haemostatic differences.
maTERıal	and	mETHOdS
The  study  was  prospectively  conducted  at  Osmangazi 
University Medical Faculty, Nephrology Department. 
30  diabetic  patients  under  follow-up  at  the  Nephrology 
Polyclinic, diagnosed at least 1 year ago (10 normoalbuminuric, 
10 microalbuminuric, 10 macroalbuminuric), 10 patients newly 
diagnosed  with  idiopathic  nephropathic  syndrome  and  12 
healthy controls were included in the study. All of the diabetic 
patients  (18  female,  12  male)  were  diagnosed  with  diabetes 
mellitus type 2. The disease duration of diabetic patients was 
60.3±13.24  months. Among  the  type  2  diabetic  patients,  19 
were on insulin and 11 were using oral hypoglycemic drugs. 
Nephrotic syndrome was defined as plasma albumin <3g/dl and 
urinary protein excretion >3.5 g/day (derived from a 24-hour 
urine collection). Oedema was usually but not always present.
The  patients  receiving  anticoagulant  therapy  or 
contraceptives, those with a recent thromboembolic event, liver 
disease, acute or chronic infection or inflammation, and those 
with creatinine clearance below 35 ml/min were excluded from 
the study.
The  albumin  excretion  rate  was  calculated  from  a  24-
hour  urine  collection  after  ruling  out  urinary  infection  and 
haematuria. Albumin  excretion  of  0-30  mg/day  was  defined 
as normoalbuminuria, values between 30 to 300 mg/day with 97
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multiple comparison tests. Score variables between the 2 groups 
were  compared  using  the  Mann-Whitney  U  test.  Spearman 
correlation analysis was used to determine correlations among 
non-normally  distributed  variables.  P  <  .05  was  accepted  as 
statistically significant.
Continuous normally distributed measurements were compared 
across the groups using 1-way analysis of variance using the 
Student-Newman-Keuls method for multiple comparisons. Score 
variables that did not demonstrate a normal distribution were 
compared using the Kruskal-Wallis test with the Dunn method 
Table	ı: Demographic characteristics and basic laboratory data of the patients and control group.
Control	group	
(n:12)
nephrotic	
syndrome	
(n:10)
normoalbu-
minüric	dia-
betic	patient	
(n:10)
microalbu-
minüric	dia-
betic	patient	
(n:10)
macroal-
buminüric	
diabetic	patient	
(n:10)
p
 Sex(M/F) 7/5 7/3 6/4 7/3 5/5
*Age(yıl) 35.75±13.98 33.6±12.6 58.5±11.98 59.4±15.14 63±13.38 p<0.001
*height (cm) 170.75±11.87 168±7.21 161.20±10.39 167.5±7.66 162.90±6.14 p>0.05
**weight (kğ) 66.5 (57.5-72.5) 62.5 (58-78) 64.35 (59-72) 76 (70-86) 65 (62-85) p>0.05
**BMI(kg/m²)
21.99
(21.01-24.66)
22.21
(21.48-24.92)
25.87
(21.8-27.7)
28.76
(25.73-30)
23.85
(23.55-31.24)
p<0.05
**Hemoglobin
b(g/dl) (13.3-17.7)
14.35
(12.5-15.25)
12.05
(11.1-13)
13.45
(11.9-15.5)
12.7 (11.6-14)
12.6
(12.3-13.5)
p>0.05
*WBC(10³/ul)(3.9-10.6) 7.325±1.98 8.09±2.45 8.66±1.59 8.75±2.27 8.76±2.12 p>0.05
*Platelets count 235000±55.68 307.900±69.67 308400±87.28 308500±8027 284000±91.83 p>0.05
** Glucose (mg/dl)(70-110) 78 (75-82.5) 81.5 (74-90) 130.5 (99-220)
151.5
(117-202)
134 (96-188) P<0.001
**Total cholesterol,
(mg/dl)(112-200)
166.5 (151-186) 288 (179-352) 171.5 (161-209) 167 (145-196) 182.5 (162-213) p<0.05
**Triglycerides
(mg/dl) (25-170)
76.5 (54-97.5) 250.5 (26-295) 136 (85-201) 149 (87-372) 173.5 (89-204) p<0.001
**HDL –C
 (mg/dl) (35-70)
54 (46-57.5) 40.5 (36-61) 42 (40-50) 41 (36-53) 44.5 (39-52) p>0.05
**LDL- C (mg/dl) 100.4 (82.3-114.9) 148 (113.8-209)
105.5
(96.2-123)
83.6 (64-98.4) 103.6 (83-130) p<0.05
**BUN (mg/dl)(5-20) 14 (12-17) 15.05 (12-26.8) 17.5 (13-30) 18.5 (15-26) 19.9 (11-34.1) p>0.05
**Cr (mg/dl)(0.5-1.6) 0.75 (0.7-0.85) 0.9 (0.6-1.4) 0.84 (0.6-1.13) 0.8 (0.61-1) 1.15 (0.8-1.2) p>0.05
**Total Protein (g/dl)(6-8.5) 7.75 (7.5-7.95) 5.1 (4.3-5.7) 7.6 (7-7.8) 7.55 (6.4-8.2) 6.8 (6.7-7.7) p<0.001
*Albumin (g/dl)(3.5-5) 4.62±0.35 2.48±0.53 4.45±0.33 4.4± 0.68 4.08±0.5 p<0.001
*CrCl (ml/dk) 101.37±13.33 90.54±42.63 92.56±27.80 85.31±35.32 75.76±39.9 p>0.05
**Proteinüri a (mg/gün) 90.34 (71.25-111.5)
5143
(4525-7290)
128.1
(87.9-166.59)
333.28
(240-593.76)
834.6 (604-1082) p<0.001
**Microalbuminüria
(mg/gün)
10.3 (6.73-12.42)
1416
(838-2405)
8.36 (5.8-21.56)
128.76
(63.9-194)
538.8 (429-669) p<0.001
Bmı, body mass ındex; wBC, white blood count; ldl-C, low-density lipoprotein cholesterol; Hdl-C, high- density lipoprotein 
cholesterol; Bun, blood urea nitrogen; Cr, creatinine; CrCı, creatinine clearance
Values are given as mean (SD) or median (range).
* One Way Analysis of Variance, mean(SD)
 ** Kruskal-Wallis test, median(Q1-Q3)Özkurt S et al : Haemostatic Changes in Patients with
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of  microalbuminuric  diabetic  patients  was  also  significantly 
higher than the control group (412 mg/dl (361-433), 280.5 mg/
dl (270.5-301.5) respectively) (p<0.001) while the fibrinogen 
values  were  similar  between  the  other  groups  (p>0.05). AT-
III value of the patients with NS was significantly lower than 
the control group and the macroalbuminuric diabetic patients 
(24.35 mg/dl (20.6-25.6), 32.1 mg/dl (25.3-45.9), 31.5 mg/dl 
(27.9-36.4), respectively) (p<0.05) while the AT-III values were 
similar between the other groups (p>0.05). We found different 
levels of FVIII across the group yet we could not calculate this 
during the multiple comparison; however, the FVIII level was 
within the normal reference range of our laboratory. The groups 
did not show any difference in terms of protein S level, protein 
C activity, FVII, FIX, FXI, and plasminogen values (p>0.05).
dıSCuSSıOn
In  this  study,  antithrombin  III  levels  of  patients  with 
nephrotic syndrome were significantly lower than the control 
group  and  macroalbuminuric  diabetics  but  fibrinogen  levels 
were  significantly  higher  than  controls.  Fibrinogen  levels  of 
microlalbuminuric  diabetics  were  significantly  higher  than 
controls. Other haemostatic parameters were all in normal range 
in all patient groups.
Elevated levels  of  fibrinogen  is  a  marked  abnormality in 
patients with nephrotic syndrome (6, 8-10, 11, 12). In the study 
by Takeda and Chen, the elevated plasma fibrinogen level was 
observed to be a result of urinary protein loss and the proportionally 
increased synthesis (13). In our study, plasma fibrinogen level of 
RESulTS
The  demographic  characteristics  and  the  basic  laboratory 
data of the patients and control group are presented in Table I, 
and the haemostatic data in Table II.
The  height,  body  weight,  haemoglobin  (Hb),  white 
blood  count  (WBC),  platelet  count,  high-density  lipoprotein 
cholesterol  (HDL-C),  blood  urea  nitrogen  (BUN),  creatinine 
(Cr), and creatinine clearance (CrCI) data were similar between 
the patients and the control group (p> 0.05). The age of patients 
in NS and control groups (33.6±12.6 and 35.75±13.98 years, 
respectively) were statistically lower than the normoalbuminuric, 
microalbuminuric and macroalbuminuric ones among diabetic 
patients  (58.5±11.98,  59.4±15.14  and  63±13.38  years, 
respectively) (p<0.001) while the ages were similar between 
the NS and control groups (p>0.05). Body mass index (BMI) 
of the microalbuminuric diabetic patients was higher than the 
control group with statistical significance (28.76 mg/m² (25.73-
30)  and  21.99  mg/m²  (21.01-24.66),  respectively)  (p<0.05) 
while the BMI of other groups were similar (p>0.05). We found 
difference between the groups regarding total cholesterol levels, 
yet we could not calculate this during the multiple comparison; 
however,  the  median  value  of  the  patients  with  NS  was 
significantly higher compared to other groups (p<0.05). 
The fibrinogen value of the patients with NS was significantly 
higher than the control group and the normoalbuminuric diabetic 
patients (496 mg/dl (429-625), 280.5 mg/dl (270.5-301.5), 337 
mg/dl (265-366), respectively) (p<0.001); the fibrinogen value 
Table	ıı: Comparison between the haemostatic paramaters of patient groups and control groups.
Control	group	
(n:12)
nephrotic	
syndrome	
(n:10)
normoalbu-
minüric	dia-
betic	patient
(n:10)
microalbu-
minüric	dia-
betic	patient
(n:10)
macroalbu-
minüric	dia-
betic	patient
(n:10)
p
*Protein.S (%) (55-140) 91.017±19.44 87.75±22.69 89.41±18.85 89.91±28.16 77.19±24.05 p>0.05
*Protein.C aktivity(%)
(70-130)
112.3±13.04 133.5±29.72 122.30±22.61 117±21.11 116.30±26.51 p>0.05
**ATIII (mg/dl) (25-36) 32.1 (25.3-45.9) 24.35 (20.6-25.6) 29.5 (26.8-32.5) 31.1 (23.6-34.3) 31.5 (27.9-36.4) p<0.05
*FVII (%) (50-150) 118.31±21.76 128.06±35.52 116.74±35.94 120.2±20.72 103.76±25.26 p>0.05
*FVIII (%) (50-150) 106.76±25.86 136.18±24.61 142.08±44.92 133.94±42.63 107.21±21.36  p<0.05
*FIX (%) (50-150) 118.23±31.16 122.24±37.17 111.19±25.52 131.14±39.50 119.75±31.94  p>0.05
*FXI (%) (50-150) 103.83±27.50 99.29±27.53 125.88±14.83 120.34±31.90 123.06±50.17 p>0.05
*Plazminogen(%) (80.2-
132.5)
102.50±18.59 91.67±15.06 99.40±16.46 105±16.51 105.90±15.91 p>0.05
**Fibrinogen(mg/dl)
(200-400)
280.5
(270.5-301.5)
496 (429-625) 337 (265-366) 412 (361-433) 383 (288-525) p<0.001
aTııı, antithrombin 3; FVıı, factor 7; FVııı, factor 8; FıX,	factor 9; FXı;	factor 11
Values are given as mean (SD) or median (range).
* One Way Analysis of Variance, mean(SD)
** Kruskal-Wallis test, median(Q1-Q3)99
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while they found higher levels of urinary AT-III in patients with 
diabetic  nephropathy  and  attributed  this  to  the  non-selective 
protein loss in advanced diabetic nephropathy or the urinary 
loss due to increased local concentrations of AT-III resulting 
from  intraglomerular  thrombosis  (20).  This  study  shows  the 
loss  of  natural  anticoagulants  via  urine  in  severely  diabetic 
nephropathy and therefore appears to support our hypothesis. 
Differing  from  ours,  the  mean  creatinine  clearance  of  the 
patients is below 35 ml/min and the daily protein excretion is 
approximately  4  g/day  in  this  study. As  massive  proteinuria 
usually accompanies renal dysfunction and taking into account 
the effects of uremic nephropathy on coagulation, we excluded 
the patients with creatinine clearance below 35 ml/min and the 
ones with proteinuria at nephrotic borderline. We also could not 
investigate AT-III levels in the urine. In our study, the AT-III level 
of the nephrotic patients was lower than the diabetic patients 
in the macroalbuminuric phase with a statistically significant 
difference, and was similar to normo- and microalbuminuric 
diabetic patients; however, the AT-III level of diabetic patients 
was within the normal reference range. The finding that AT-
III level of the nephrotic patients was similar to normo- and 
microalbuminuric  diabetic  patients  while  it  was  lower  than 
the macroalbuminuric patients suggests that AT-III is not lost 
via proteinuria but the urinary levels should be investigated to 
ensure the accuracy of this observation. There was a negative 
association between the degree of proteinuria and AT-III level 
in  patients  with  nephrotic  syndrome,  although  this  was  not 
statistically significant (r =-236, p>0.05). 
In patients with nephrotic syndrome, Factor IX, XI and XII 
are likely to be lost in urine due to their low molecular weight. 
While the level of Factor IX varied, the levels of factor XI and 
XII were low in patients with nephrotic syndrome. The levels 
of co-factors, Factor V and VIII were increased (21). Kanfer 
and colleagues demonstrated F VIII activity exceeding 200% in 
22 of 57 patients with nephrotic syndrome (9). These changes 
lead to increased synthesis of these proteins from the liver due 
to  decreased  plasma  oncotic  pressure,  F V  and VIII  are  not 
found in the urine of patients with nephrotic syndrome, and this 
may be related to their molecular size (21). In our study, the 
factor levels of the patients with nephrotic syndrome and the 
normo-micro-macroalbuminuric diabetic patients were within 
the normal reference range of our laboratory. The coagulation 
and fibrinolysis alterations in urine and glomerulus of patients 
with  nephrotic  syndrome  are  not  fully  understood  and  there 
are  controversial  results.  Generally,  the  plasma  plasminogen 
concentration is decreased in nephrotic syndrome (22-24). This 
has been associated with the low level of serum albumin and the 
degree of proteinuria (25,26). In our study, we found a lower 
plasminogen level in patients with nephrotic syndrome compared 
to the control group, although this difference was not statistically 
significant.  There  was  no  difference  regarding  plasminogen 
levels between the normo-micro-macroalbuminuric patients and 
the patients with nephrotic syndrome. 
patients with nephrotic syndrome was significantly higher than 
the control group and normoalbuminuric diabetic patients, while 
it was similar to those of micro- and macroalbuminuric diabetic 
patients.  While  the  fibrinogen  level  of  normoalbuminuric 
patients was not different from the control group in our study, the 
fibrinogen level of microalbuminuric patients was significantly 
higher than the control group; however, the lack of a difference 
between  the  fibrinogen  levels  of  macroalbuminuric  patients 
and the control group suggests that this situation is not related 
to proteinuria. In that case, the hyperfibrinogenemia in type II 
diabetes may be occurring due to a different mechanism than the 
hyperfibrinogenemia in nephrotic syndrome. As the reason of 
this, Knöbl et al. suggested the adhesion of monocytes with the 
disrupted endothelium due to diabetic vasculopathy, which leads 
to release of interleukin 6, causing increased hepatic synthesis 
of fibrinogen (14). The majority of the studies report elevated 
fibrinogen levels in Type II diabetic patients with or without a 
microvascular disorder (15).
There are articles reporting loss of coagulation inhibitors such 
as protein C and protein S in patients with nephrotic syndrome 
due to massive proteinuria and increased production in the liver 
as compensation (16, 17); therefore, the plasma levels of these 
proteins are either normal or increased but the protein C activity 
or the functional level of protein S may be decreased (16, 17). We 
found normal levels of protein C activity and protein S, which 
were not different than the control group. Similar to our study, 
Aslan et al. classified Type II diabetic patients into subgroups 
based on urinary albumin excretion: group 1 (<30 mg/ml), group 
2 (30-140 mg/ml) and group 3 (>140 mg/ml), and performed 
assays for protein C antigen and protein C activity. While the 
mean protein C-antigen (ag) levels in group 1, 2 and 3 were 
lower than the control group, the protein C activity levels of the 3 
groups were not different than the control group (18). According 
to  this  study,  the  finding  that  even  the  normoalbuminuric 
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As a result of our study, we find it difficult to attribute the 
hypercoagulability in patients with nephrotic syndrome to the 
elevated fibrinogen, which we consider as possibly related to 
proteinuria, and the mild AT-III deficiency. There are articles 
reporting  that  nephrotic  syndrome  accompanies  acquired 
hypercoagulability; however, it leads to thrombotic events in 
the presence of an underlying genetic thrombophilia (27, 28). 
Furthermore,  use  of  diuretics  and  steroids  are  also  thought 
to  facilitate  thrombosis.  Similarly,  the  lack  of  haemostatic 
problems  in  diabetic  patients  in  macroalbuminuric  phase 
make  it  difficult  to  explain  the  hypercoagulation  mechanism 
with  proteinuria  alone.  In  addition,  it  is  difficult  to  explain 
hypercoagulation  mechanism  with  proteinuria  alone  in  these 
patients as the different glycemic control levels and different 
treatment approaches in diabetics with various levels of vascular 
complications, and various type and duration of diabetes may 
have an impact on haemostatic parameters. Another limitation 
of  our  study  is  the  limited  number  of  our  patients  and  the 
younger age in patients with nephrotic syndrome while the type 
II diabetic patients were at an advanced age.
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